According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
A number of other equities research analysts have also recently issued reports on the stock. Citigroup Inc. reduced their target price on shares of MacroGenics from $32.00 to $24.00 and set a neutral rating for the company in a research report on Wednesday, January 25th. SunTrust Banks, Inc. assumed coverage on shares of MacroGenics in a research report on Monday, December 19th. They issued a buy rating and a $30.00 target price for the company. Roth Capital reissued a buy rating on shares of MacroGenics in a research report on Wednesday, November 16th. TheStreet cut shares of MacroGenics from a hold rating to a sell rating in a research report on Tuesday, November 8th. Finally, BTIG Research reissued a buy rating and issued a $35.00 target price on shares of MacroGenics in a research report on Monday, November 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $34.75.
Shares of MacroGenics (NASDAQ:MGNX) opened at 19.30 on Wednesday. The firm’s market cap is $672.32 million. The stock has a 50 day moving average of $19.29 and a 200-day moving average of $25.61. MacroGenics has a 52 week low of $14.85 and a 52 week high of $33.30.
“MacroGenics, Inc. (MGNX) Stock Rating Upgraded by Zacks Investment Research” was originally published by BBNS and is the property of of BBNS. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/macrogenics-inc-mgnx-stock-rating-upgraded-by-zacks-investment-research/434961.html.
A number of large investors have recently bought and sold shares of MGNX. Teacher Retirement System of Texas boosted its stake in MacroGenics by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 466 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in MacroGenics during the fourth quarter valued at $186,000. SG Americas Securities LLC purchased a new stake in MacroGenics during the third quarter valued at $223,000. Wells Fargo & Company MN boosted its stake in MacroGenics by 42.1% in the third quarter. Wells Fargo & Company MN now owns 13,029 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 3,858 shares in the last quarter. Finally, Royal Bank of Canada boosted its stake in MacroGenics by 1,122.9% in the second quarter. Royal Bank of Canada now owns 14,430 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 13,250 shares in the last quarter. 81.68% of the stock is owned by institutional investors and hedge funds.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with our FREE daily email newsletter.